Tenoxicam. Pharmacological and clinical profile
https://doi.org/10.14412/2074-2711-2025-1-94-101
Abstract
The review contains information on the pharmacodynamics, pharmacokinetics and clinical pharmacology of the non-steroidal anti-inflammatory drug (NSAID) tenoxicam (trade name – Texared®). Some features of the chemical structure of tenoxicam and the specificity of pharmacological action based on them are discussed, as well as clinical effects that distinguish tenoxicam from its homologues. The efficacy is compared with that of other NSAIDs. Issues of clinical pharmacokinetics (low dissociation constant – pK; exposure levels; long T0.5; Cmax, etc.) are discussed. The clinical part of the review presents comparative studies on tenoxicam and its homologues as well as on combinations of tenoxicam with drugs from other groups.
Keywords
non-steroidal anti-inflammatory drugs,
pain syndromes and their treatment,
tenoxicam,
Texared®,
combinations of drugs
Supporting agencies: The article is sponsored by Dr. Reddy’s.
About the Authors
V. V. Afanasyev
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Vasily Vladimirovich Afanasyev
47, Piskarevsky Prosp., pavilion 12, St. Petersburg 195067
Competing Interests:
The conflict of interests did not affect the results of the study
D. A. Iskra
Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
47, Piskarevsky Prosp., pavilion 12, St. Petersburg 195067
Competing Interests:
The conflict of interests did not affect the results of the study
References
1. Fenner H. Comparative biochemical pharmacology of the oxicams. Eur J Rheumatol Inflamm. 1987;9(2):3-7.
2. Arkhipov SG, Sherin PS, Kiryutin AS, et al. The role of S-bond in tenoxicam keto-enolic tautomerization. Cryst Eng Comm. 2019;21:5383-402. doi: 10.1039/C9CE00874H
3. Araujo de Oliveira AP, Wegermann C, Da Costa Ferreira A. Keto-enol tautomerism in the development of new drug. Front Chem Biol. 2024;(3):1542-55. doi: 10.3389/fchbi.2024.1400642
4. Vinogradov VM, Gembitsky EV, Mukhin EA, Frolov SF. Pharmacology (General, Specific and Clinical Fundamentals). Textbook. Ed. by V.M. Vinogradov. 2nd ed., suppl. and revised. Leningrad: VMA; 1985. 515 p. (In Russ.).
5. Zhang YY, Yao YD, Luo JF, et al. Microsomal prostaglandin E2 synthase-1 and its inhibitors: Molecular mechanisms and therapeutic significance. Pharmacol Res. 2022 Jan;175:105977. doi: 10.1016/j.phrs.2021.105977. Epub 2021 Nov 17.
6. Rouzer CA, Marnett LJ. Structural and Chemical Biology of the Interaction of Cyclooxygenase with Substrates and Non-Steroidal Anti-Inflammatory Drugs. Chem Rev. 2020 Aug 12;120(15):7592-641. doi: 10.1021/acs.chemrev.0c00215. Epub 2020 Jul 1.
7. Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec;66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23.
8. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099-108. doi: 10.1016/0006-2952(73)90196-2
9. Butranova OI, Zyryanov SK. Selection of NSAIDs for rational pharmacotherapy of chronic musculoskeletal pain: a clinical pharmacologist's perspective. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):87- 94. doi: 10.14412/2074-2711-2024-2-87-94 (In Russ.).
10. Bonanni R, Cariati I, Tancredi V, et al. Chronic Pain in Musculoskeletal Diseases: Do You Know Your Enemy? J Clin Med. 2022 May 6;11(9):2609. doi: 10.3390/jcm11092609
11. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002 Jul;110(1):61-9. doi: 10.1172/JCI14752. Erratum in: J Clin Invest. 2002 Aug;110(3):419.
12. Girard J-P, Jeunet FS. Effect on some leucocyte functions of two oxicams. Presented at the EULAR Symposium, Rome, 16–18 Oct, 1986.
13. König W, Brom J, Schönfeld W, et al. Effect of tenoxicam and indomethacin on the release of histamine, prostaglandin E2 and leukotrienes from various cells. Arzneimittelforschung. 1987 Mar;37(3):296-9.
14. Bradshaw D, Cashin CH, Kennedy AJ, Roberts NA. Pharmacological and biochemical activities of tenoxicam (Ro 12-0068), a new non-steroidal anti-inflammatory drug. Agents Actions. 1984 Dec;15(5-6):569-77. doi: 10.1007/BF01966776
15. Gonzalez JP, Todd PA. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1987 Sep;34(3):289-310. doi: 10.2165/00003495-198734030-00001. Erratum in: Drugs. 1988 Jan;35(1):preceding 1.
16. Christophidis N, Angelis P, Mahlis E, Liolios L. Effects of tenoxicam on polymorph respiratory burst and bactericidal activity. Presented at the 6th EULAR Symposium, Athens, 16–19 May, 1990.
17. Franchimont P, Bassleer C. New diagnostic tools and methodological approaches: an outlook to the future. Scand J Rheumatol Suppl. 1989;80:29-31. doi: 10.3109/03009748909103709
18. Vignon E, Richard M. In vitro study of non-steroidal anti-inflammatory drugs (NSAIDs) on osteoarthritic cartilage matrix degenerative enzymes. Presented at the sixth EULAR Symposium, Athens, 16–19 May, 1990.
19. Ghose K, Burch A. Measurement of renal functions by double isotope techniques in elderly patients during tenoxicam therapy. Arch Gerontol Geriatr. 1989 Sep-Oct;9(2):115-22. doi: 10.1016/0167-4943(89)90032-0
20. McAuslane JAN, Freestone S, Cowie J, Prescott LF. Tenoxicam: effect on renal function in normal man. Brit J Clin Pharmacol. 1988;25:93P-94P.
21. Bird HA, Le Gallez P, Astbury C, et al. parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica. 1986;4(7):457-62.
22. Lapeyre-Mestre M, Grolleau S, Montastruc JL; Association Francaise des Centres Regionaux de Pharmacovigilance (CRPV). Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002–2006. Fundam Clin Pharmacol. 2013 Apr;27(2):223- 30. doi: 10.1111/j.1472-8206.2011.00991.x. Epub 2011 Sep 20.
23. Moya-Hernandez R, Gomez-Balderas R, Mederos A, et al. Complex formation of the antiinflammatory drugs tenoxicam and piroxicam with Fe(III) in methanol and acetone. J Coord Chem. 2009;62:40-51.
24. Chakraborty S, Bose M, Sarkar M. Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Mar 25;122:690-7. doi: 10.1016/j.saa.2013.11.078. Epub 2013 Dec 1.
25. Tasaki Y, Yamamoto J, Omura T, et al. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Neurosci Lett. 2012 Jul 11;521(1):15-9. doi: 10.1016/j.neulet.2012.05.045. Epub 2012 May 19.
26. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003 Jul;58(7):447-74.
27. Donald RA. Uges, TIAFT Bulletin of the International Association of Forensic Toxicologist. 1996. Vol. 26(1) Suppl.
28. Micromedex, Inc. Thompson Series; Drugdex, Poisondex, 2016–2020 (rev).
29. Guentert TW, Heintz RC, Joly R. Overview on the pharmacokinetics of tenoxicam. Eur J Rheumatol Inflamm. 1987;9(2):15-25.
30. Day RO, Williams KM, Graham S, Handel M. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Arthritis Rheum. 1991 Jun;34(6):751-60. doi: 10.1002/art.1780340617
31. Heintz RC, Guentert TW, Enrico JF, et al. Pharmacokinetics of tenoxicam in healthy human volunteers. Eur J Rheumatol Inflamm. 1984;7(2):33-44.
32. Esselinckx W, Stenier P. Double blind comparative study of tenoxicam in arthrosis of the knee and hip. Curr Ther Res. 1990;48:206-15.
33. Horber FF, Guentert TW, Weidekamm E, et al. Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharmacol. 1986;29(6):697-701. doi: 10.1007/BF00615961
34. Caughey D, Waterworth RF. A study of the safety of tenoxicam in general practice. N Z Med J. 1989 Nov 8;102(879):582-3.
35. Standel W, Josenhants G. Clinical evaluation of tenoxicam in osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis. Eur J Rheumatol Inflamm. 1985;8(1):28-38.
36. Simpson J, Golding DN, Freeman AM, et al. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. Br J Clin Pract. 1989 Sep;43(9):328-33.
37. Waterworth RF, Waterworth SM, Taylor KM. A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. Eur J Rheumatol Inflamm. 1985;8(1):21-7.
38. Riedemann PJ, Bersinic S, Cuddy LJ, et al. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol. 1993 Dec;20(12):2095-103.
39. Schwarzer AC, Cohen M, Arnold MH, et al. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin. 1990;11(10):648-53. doi: 10.1185/03007999009112691
40. Colbert SA, McCrory C, O'Hanlon DM, et al. A prospective study comparing intravenous tenoxicam with rectal diclofenac for pain relief in day case surgery. Eur J Anaesthesiol. 1998 Sep;15(5):544-8. doi: 10.1046/j.1365-2346.1998.00350.x
41. Ejstrup L, Knudsen JV, Petersen L. A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. Scand J Rheumatol Suppl. 1989;80:48-53. doi: 10.3109/03009748909103712
42. Villa Alcazar LF, de Buergo M, Rico Lenza H, Montull Fruitos E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol. 1996 Jul;23(7):1194-9.
43. Sutherland CJ, Montgomery JE, Kestin IG. A comparison of intramuscular tenoxicam with intramuscular morphine for pain relief following tonsillectomy in children. Paediatr Anaesth. 1998;8(4):321-4. doi: 10.1046/j.1460-9592.1998.00220.x.
Review
For citations:
Afanasyev VV, Iskra DA. Tenoxicam. Pharmacological and clinical profile. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(1):94-101. (In Russ.) https://doi.org/10.14412/2074-2711-2025-1-94-101
Views:
193
Email this article 